ATE233558T1 - Verwendung von strontiumsälze zur behandlung von arthrose - Google Patents

Verwendung von strontiumsälze zur behandlung von arthrose

Info

Publication number
ATE233558T1
ATE233558T1 AT97401362T AT97401362T ATE233558T1 AT E233558 T1 ATE233558 T1 AT E233558T1 AT 97401362 T AT97401362 T AT 97401362T AT 97401362 T AT97401362 T AT 97401362T AT E233558 T1 ATE233558 T1 AT E233558T1
Authority
AT
Austria
Prior art keywords
strontium salts
arthrosis
treat
treat arthrosis
strontium
Prior art date
Application number
AT97401362T
Other languages
English (en)
Inventor
Yannis Tsouderos
Pascale Deloffre
Michel Wierzbicki
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of ATE233558T1 publication Critical patent/ATE233558T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)
AT97401362T 1996-06-17 1997-06-16 Verwendung von strontiumsälze zur behandlung von arthrose ATE233558T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9607475A FR2749759B1 (fr) 1996-06-17 1996-06-17 Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose

Publications (1)

Publication Number Publication Date
ATE233558T1 true ATE233558T1 (de) 2003-03-15

Family

ID=9493102

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97401362T ATE233558T1 (de) 1996-06-17 1997-06-16 Verwendung von strontiumsälze zur behandlung von arthrose

Country Status (16)

Country Link
US (1) US5856356A (de)
EP (1) EP0813869B1 (de)
JP (1) JP3935557B2 (de)
CN (1) CN1136856C (de)
AT (1) ATE233558T1 (de)
AU (1) AU711950B2 (de)
BR (1) BR9703603A (de)
CA (1) CA2206837C (de)
DE (1) DE69719408T2 (de)
DK (1) DK0813869T3 (de)
ES (1) ES2193337T3 (de)
FR (1) FR2749759B1 (de)
HU (1) HU227935B1 (de)
NO (1) NO315840B1 (de)
NZ (1) NZ328106A (de)
ZA (1) ZA975323B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
FR2844795B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844797B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2846558B1 (fr) * 2002-11-05 2006-07-14 Servier Lab Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales
WO2004084920A2 (en) * 2003-03-27 2004-10-07 Santosolve As Anti-inflammatory treatment based on strontium compounds
PL1622629T3 (pl) * 2003-05-07 2013-12-31 Osteologix As Kompozycja do kontrolowanego uwalniania zawierająca sól strontu
CA2524610C (en) * 2003-05-07 2014-03-25 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
AU2004237439B2 (en) * 2003-05-07 2009-09-10 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
AU2005216596B2 (en) * 2004-02-26 2011-03-24 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
AU2005240257B2 (en) * 2004-05-06 2011-11-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
JP2008502609A (ja) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
AU2005254154A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improving pain treatment with strontium combinations
WO2006089546A1 (en) * 2005-02-28 2006-08-31 Osteologix A/S Tablets comprising a high load of strontium
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
ATE443541T1 (de) * 2004-06-25 2009-10-15 Strontin Aps Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
CN101018586B (zh) * 2004-06-25 2014-08-27 莫克瓦洛Spf有限公司 含锶和维生素d的组合物及其用途
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20140099364A2 (en) 2004-10-08 2014-04-10 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
FR2899895B1 (fr) 2006-04-12 2010-09-17 Servier Lab Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2007137653A1 (en) 2006-05-26 2007-12-06 Baxter International Inc. Injectable fibrin composition for bone augmentation
GB0612028D0 (en) * 2006-06-16 2006-07-26 Imp Innovations Ltd Bioactive glass
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101204375B (zh) * 2006-12-19 2010-09-29 北京德众万全药物技术开发有限公司 一种雷奈酸锶干混悬剂
CA2686820C (en) * 2007-04-23 2016-06-28 Baxter International Inc. Fibrin compositions containing strontium compounds
GB0713094D0 (en) * 2007-07-05 2007-08-15 Imp Innovations Ltd Glass polycarboxylate cements
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
CA2716872C (en) 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
GB2475799A (en) * 2008-05-27 2011-06-01 Imp Innovations Ltd Hypoxia inducing factor (hif) stabilising glasses
GB0809592D0 (en) * 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials
PT2379063E (pt) 2009-01-09 2013-05-03 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
WO2011110597A1 (de) 2010-03-11 2011-09-15 Azad Pharmaceutical Ingredients Ag Verfahren zur herstellung von strontiumranelat
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
AU2011260260B2 (en) 2010-06-01 2015-09-03 Baxter Healthcare S.A. Process for making dry and stable hemostatic compositions
EP2530068A1 (de) 2011-05-31 2012-12-05 Lacer, S.A. Neue Strontiumsalze, deren Synthese und Verwendung bei der Behandlung von Osteoporose
ES2938566T3 (es) 2011-10-11 2023-04-12 Baxter Int Composiciones hemostaticas
KR102102002B1 (ko) 2011-10-11 2020-04-20 백스터 인터내셔널 인코포레이티드 지혈 조성물
SA112330957B1 (ar) 2011-10-27 2015-08-09 باكستر انترناشونال انك. تركيبات لإيقاف النزف
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
BR112014030962A2 (pt) 2012-06-12 2017-06-27 Ferrosan Medical Devices As métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático
RU2700162C2 (ru) 2013-06-21 2019-09-13 Ферросан Медикал Дивайсиз А/С Расширенная под вакуумом сухая композиция и шприц для ее сохранения
EP3470094B1 (de) 2013-12-11 2020-07-22 Ferrosan Medical Devices A/S Trockenzusammensetzung mit extrusionsverstärker
CA2960309A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
CN107206165B (zh) 2014-12-24 2020-10-23 弗罗桑医疗设备公司 用于保持并混合第一和第二物质的注射器
AU2016290433B2 (en) 2015-07-03 2018-05-24 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US10463636B2 (en) 2016-09-30 2019-11-05 Deanna J. Nelson Pharmaceutical quality strontium L-lactate
WO2019215274A1 (en) 2018-05-09 2019-11-14 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152431A (en) * 1977-09-22 1979-05-01 William H. Rorer, Inc. Compositions and method of use
FR2633619B1 (fr) * 1988-06-29 1991-02-08 Adir Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
AU711950B2 (en) 1999-10-28
HU9701059D0 (en) 1997-08-28
CN1179944A (zh) 1998-04-29
DK0813869T3 (da) 2003-06-02
FR2749759A1 (fr) 1997-12-19
NO972764L (no) 1997-12-18
FR2749759B1 (fr) 1999-11-26
EP0813869B1 (de) 2003-03-05
HU227935B1 (en) 2012-06-28
CA2206837C (fr) 2002-12-03
AU2490297A (en) 1998-01-08
DE69719408D1 (de) 2003-04-10
HUP9701059A2 (hu) 1998-03-02
CA2206837A1 (fr) 1997-12-17
JPH1059852A (ja) 1998-03-03
CN1136856C (zh) 2004-02-04
NZ328106A (en) 2001-04-27
ES2193337T3 (es) 2003-11-01
DE69719408T2 (de) 2003-12-24
US5856356A (en) 1999-01-05
NO315840B1 (no) 2003-11-03
BR9703603A (pt) 1998-09-01
NO972764D0 (no) 1997-06-16
ZA975323B (en) 1998-01-14
EP0813869A1 (de) 1997-12-29
JP3935557B2 (ja) 2007-06-27
HUP9701059A3 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
DE69719408T2 (de) Verwendung von Strontiumsälze zur Behandlung von Arthrose
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69703649D1 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
DK130387A (da) Transglutaminase inhibitorer
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE95694T1 (de) Verwendung von bezafibrat zur behandlung von diabetes.
DE69331833T2 (de) Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose
DE69305267D1 (de) Zusammensetzung zur Behandlung von Mastitis und Metritis
DE58902451D1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE59709081D1 (de) Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung und Prävention der Alzheimer'schen Krankheit
ATA96097A (de) Verwendung von queller zur behandlung oder prophylaxe von jodmangelerscheinungen
ATE214923T1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
DE69117566D1 (de) Verwendung von Isomonoolen zur Behandlung und Prophylaxe von Krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0813869

Country of ref document: EP